← SynDRA
MAVACAMTEN
SynDRA canonical compound SYN0039663 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | MYH7 |
|---|
| Mechanism of action | myosin inhibitor |
|---|
All known targets
- MYH7
- MYH6
- MYH7B
- MYL2
- MYL3
- MYL4
- MYL7
Mechanisms of action (all sources)
- MYH7 INHIBITOR
- Cardiac myosin inhibitor
- MYH6 INHIBITOR
- MYH7B INHIBITOR
- MYL3 INHIBITOR
- MYL2 INHIBITOR
- MYL7 INHIBITOR
- MYL4 INHIBITOR
- myosin inhibitor
ATC classes
- C01E · OTHER CARDIAC PREPARATIONS
Cross-references
Synonyms
- camzyos
- MYK-461
- SAR-439152
- Camzyos
- SAR 439152
- SAR439152
- MYK 461
- MYK461
- QX45B99R3J
- mavacamtenum
- RefChem:58370
- MFCD31746877
- Mavacamten [INN]
- Mavacamten [USAN]
- Mavacamten [WHO-DD]
- Mavacamten (MYK-461)
- MavacamtenMYK-461
- XB2
- Camzyos (TN)
- MYK-461 (SAR-439152)
- Mavacamten (Standard)
- UNII-QX45B99R3J
- Mavacamten (JAN/USAN/INN)
- orb1300039
- SCHEMBL16320785
- GTPL11265
- Mavacamten [USAN:INN:WHO-DD]
- RLCLASQCAPXVLM-NSHDSACASA-N
- EX-A2072
- SQC28847
- BDBM50575174
- s8861
- WHO 10492
- HY-109037R
- MYK-461; Mavacamten; SAR439152
- NCGC00510355-03
- AC-37931
- DA-55251
Reported adverse events
Look up MAVACAMTEN in the interactive SynDRA portal →